Please carefully read the below information, it tells me SRX has...

Please carefully read the below information, it tells me SRX has an excellent future and positive comments will be made at ASCO:-
Sydney, Australia; 18th May 2017 – Sirtex Medical Limited (ASX:SRX) today announces the results of the 360 patient SIRveNIB clinical study comparing SIR-Spheres® Y-90 resin microspheres versus sorafenib (Nexavar®, Bayer Healthcare Pharmaceuticals)
While the primary endpoint of Overall Survival (OS) superiority versus sorafenib in the Intent to Treat analysis was not met, the SIRveNIB study showed both treatments resulted in a similar median OS in patients with statistically significant safety and toxicity favouring SIR-Spheres.
Mr Nigel Lange, Interim CEO of Sirtex Medical said “We are particularly pleased with the SIRveNIB study results. The results demonstrate that SIR-Spheres minimise the adverse effects that otherwise would diminish the quality of liver cancer patients’ survival. In addition, SIR-Spheres delivered survival outcomes that were not statistically different versus sorafenib, the only approved first-line agent for advanced HCC. We note that 29% of patients did not receive SIR-Spheres in the ITT analysis and this clearly impacted the overall survival result when compared to the overall survival data from the PP analysis. The results of SIRveNIB support similar findings in in the SARAH study, as recently reported at the EASL International Liver Congress™ 2017.”
Mr Lange continued “Our Asian business continues to perform to plan throughout FY17, and following peer review and acceptance at ASCO, we believe SIRveNIB will generate further awareness and interest in SIR-Spheres from clinicians seeking a well-tolerated alternative treatment to sorafenib in advanced HCC patients. We therefore eagerly await the oral abstract presentation at ASCO by Professor Chow on the 4th of June.”